ArticlePediatric nephrology (Berlin, Germany)2010
Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.
Article in Pediatric nephrology (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Clinicopathological characteristics and cyclosporine-responsive proteinuria in nail-patella syndrome with a novel LMX1B mutation.Pediatric nephrology (Berlin, Germany) · 2026Article
- Efficacy of Calcineurin Inhibition in Children With Steroid-Resistant Nephrotic Syndrome.Kidney international reports · 2025Article
- Article
- Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis.Frontiers of medicine · 2022Article
- How immunosuppressive drugs may directly target podocytes in glomerular diseases.Pediatric nephrology (Berlin, Germany) · 2022Review
- Control of Podocyte and Glomerular Capillary Wall Structure and Elasticity by WNK1 Kinase.Frontiers in cell and developmental biology · 2020Article
- Treatment of Genetic Forms of Nephrotic Syndrome.Frontiers in pediatrics · 2018Review
- The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.Clinical reviews in allergy & immunology · 2017Review
- Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Pediatric nephrology (Berlin, Germany) · 2016Review
- Translating genetic findings in hereditary nephrotic syndrome: the missing loops.American journal of physiology. Renal physiology · 2015Review
- Treatment of severe lupus nephritis: the new horizon.Nature reviews. Nephrology · 2015Review
- Non-immunologic actions of calcineurin inhibitors in proteinuric kidney diseases.Frontiers in endocrinology · 2014Review
- Actin-associated Proteins in the Pathogenesis of Podocyte Injury.Current genomics · 2013Article
- Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/β-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria.The Journal of biological chemistry · 2013Article
- An update on the pathomechanisms and future therapies of Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2013Review
- Childhood nephrotic syndrome--current and future therapies.Nature reviews. Nephrology · 2012Review
- The podocyte as a target for therapies--new and old.Nature reviews. Nephrology · 2011Review
- Treatment of steroid-resistant pediatric nephrotic syndrome.Korean journal of pediatrics · 2011Article
- Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Advances in chronic kidney disease · 2011Review
- New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been reported (this issue Pediatric Nephrology) that cyclosporine A (CyA) therapy in combination with corticosteroids, angiotensin-converting enzyme inhibitor, and an angiotensin receptor blocker decreased proteinuria in three patients with nephrotic syndrome (NS) due to WT1 mutations. Treatment with calcineurin inhibitors were found to induce a partial remission of proteinuria in several other children with genetic forms of NS, such as mutation in the podocine and in the phospholipase C epsilon gene. CyA therapy has also been reported to be beneficial to patients with Alport syndrome. Recent data have shown that the antiproteinuric effect of CyA in these cases may be due to a non-immunologic mechanism. CyA exerts an antiproteinuria effect by preventing the degradation of the actin organizing protein synaptodpodin and by a downregulation of TRPC6. This mechanism leads to the stabilization of the actin cytoskeleton in the kidney podocytes. This beneficial effect of CyA is interesting, but long-term results regarding function and nephrotoxicity are still missing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.